NVAX
NOVAVAX INC
$8.56
-1.33%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusBuy (67%)
Inst. Holders7 funds
Inst. Value$201.8M
Inst. Activity3 buys / 2 sells
Reddit Sentiment63° Warm
SEC Reports3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001000694·Prev Close $8.67
Recent Activity
May 28, 2026
short_volume
Short Volume: NVAX — 56.8% short (1.9M / 3.4M)
Short: 1,925,087 | Exempt: 5,156 | TRF Vol: 3,386,560 | Short Ratio: 56.8% | Off-exchange volume (da
May 6, 2026
SEC
Novavax reported Q1 2026 total revenue of $140M, down 79% YoY from $667M, which included $603M in non-cash APA close-out
8-K — Impact 4/10
Apr 27, 2026
SEC
Novavax has filed definitive additional proxy materials, indicating an active shareholder vote or corporate action. The
DEFA14A — Impact 2/10
Apr 25, 2026
Insider
Newton Charles W. sold 9,520 shares
Director @ $0.00 ($0.00)
Apr 25, 2026
Insider
Newton Charles W. sold 9,520 shares
Director @ $0.00 ($0.00)
Apr 14, 2026
Insider
Walker Robert Edward sold 99,500 shares
EVP, R&D @ $0.00 ($0.00)
Feb 26, 2026
SEC
Novavax reported strong financial results for Q4 and full year 2025, with revenue up 67% YoY to $147 million in Q4 and $
8-K — Impact 8/10
Inst.
BANK OF AMERICA CORP — DOUBLED
8,290,665 shares ($55.7M)
Price Targets
$14.11
+65.0% upside
Strong Buy
Current $8.56
Low $7.00
Median $16.02
High $25.00
9 analysts
$7.00
$25.00
Analyst Ratings
4Strong Buy
6Buy
2Hold
2Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | TD Cowen | MAINTAIN | Hold → Hold |
| Feb 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 20, 2026 | BTIG | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.40 ▼ -200.9% | $-0.50 — $-0.26 | -164% YoY | 6 |
| Next Q | $-0.15 ▼ -618.6% | $-0.44 — $0.22 | 88% YoY | 5 |
| Current FY | $-0.47 ▼ -27.2% | $-1.38 — $0.52 | -118% YoY | 9 |
| Next FY | $-0.25 ▲ +22.9% | $-0.85 — $0.80 | 46% YoY | 9 |
Latest Reports
NEUTRAL
8-K
4/10
Novavax reported Q1 2026 total revenue of $140M, down 79% YoY from $667M, which included $603M in non-cash APA close-out
May 6, 2026
NEUTRAL
DEFA14A
2/10
Novavax has filed definitive additional proxy materials, indicating an active shareholder vote or corporate action. The
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $104.0M | — |
| BANK OF AMERICA CORP | $55.7M | DOUBLED |
| MORGAN STANLEY | $25.0M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $9.0M | NEW |
| TWO SIGMA INVESTMENTS, LP | $4.2M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 25, 2026 | Newton Charles | M | $0.00 |
| Apr 25, 2026 | Newton Charles | M | $0.00 |
| Apr 14, 2026 | Walker Robert | A | $0.00 |
| Apr 14, 2026 | Walker Robert | A | $0.00 |
| Mar 10, 2026 | Shiver John | M | $0.00 |
Reddit Sentiment
63°
Warm
Bearish
Neutral
Bullish
7 institutional holders with $201.8M total value (30,029,369 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, MORGAN. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 15,470,365 | $104.0M | 51.5% | — |
| 2 | BANK OF AMERICA CORP /DE/ | 8,290,665 | $55.7M | 27.6% | DOUBLED +167.3% |
| 3 | MORGAN STANLEY | 3,717,984 | $25.0M | 12.4% | DOUBLED +245.4% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,335,053 | $9.0M | 4.4% | NEW |
| 5 | TWO SIGMA INVESTMENTS, LP | 623,812 | $4.2M | 2.1% | ADD +30.2% |
| 6 | FMR LLC | 424,941 | $2.9M | 1.4% | ADD +29.3% |
| 7 | WELLS FARGO & COMPANY/MN | 166,549 | $1.1M | 0.6% | TRIM -49.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 3,101,074 | 8,290,665 | +167.3% | $55.7M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 1,076,444 | 3,717,984 | +245.4% | $25.0M | 2025-Q4 |
| FMR LLC | ADD | 328,641 | 424,941 | +29.3% | $2.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 329,228 | 166,549 | -49.4% | $1.1M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 1,196,750 | 0 | -100.0% | $0.00 | 2025-Q4 |
| UBS Group AG | ADD | 2,284,075 | 3,544,103 | +55.2% | $30.7M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 667,647 | 1,196,750 | +79.2% | $10.4M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 539,246 | 702,000 | +30.2% | $6.1M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 2,932,164 | 329,228 | -88.8% | $2.9M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,153,087 | 3,185,389 | +176.2% | $20.1M | 2025-Q2 |
| UBS Group AG | ADD | 1,410,148 | 2,284,075 | +62.0% | $14.4M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 1,977,940 | 1,238,786 | -37.4% | $7.8M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 505,247 | 667,647 | +32.1% | $4.2M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 240,185 | 539,246 | +124.5% | $3.4M | 2025-Q2 |
| FMR LLC | ADD | 194,759 | 289,723 | +48.8% | $1.8M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 125,845 | 3,219,426 | +2458.2% | $20.6M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 4,940,115 | 1,977,940 | -60.0% | $12.7M | 2025-Q1 |
| UBS Group AG | TRIM | 4,851,757 | 1,410,148 | -70.9% | $9.0M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,407,530 | 505,247 | -64.1% | $3.2M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 30,907 | 240,185 | +677.1% | $1.5M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 1,552,219 | 4,940,115 | +218.3% | $39.7M | 2024-Q4 |
| UBS Group AG | DOUBLED | 525,354 | 4,851,757 | +823.5% | $39.0M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,064,783 | 1,407,530 | -31.8% | $11.3M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 95,864 | 125,845 | +31.3% | $1.0M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,325,508 | — | $16.7M | 2024-Q3 |
8 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 25, 2026 | Newton Charles W. | Director | M | 9,520 | $0.00 | $0.00 |
| Apr 25, 2026 | Newton Charles W. | Director | M | 9,520 | $0.00 | $0.00 |
| Apr 14, 2026 | Walker Robert Edward | EVP, R&D | A | 99,500 | $0.00 | $0.00 |
| Apr 14, 2026 | Walker Robert Edward | EVP, R&D | A | 66,000 | $0.00 | $0.00 |
| Mar 10, 2026 | Shiver John W. | Director | M | 7,947 | $0.00 | $0.00 |
| Mar 10, 2026 | Shiver John W. | Director | M | 7,947 | $0.00 | $0.00 |
| Mar 7, 2026 | Kelly James Patrick | EVP, CFO and Treasurer | F | 5,904 | $9.98 | $58.9K |
| Mar 7, 2026 | Kelly James Patrick | EVP, CFO and Treasurer | M | 12,223 | $0.00 | $0.00 |
| Mar 7, 2026 | Kelly James Patrick | EVP, CFO and Treasurer | M | 12,223 | $0.00 | $0.00 |
| Mar 3, 2026 | Kelly James Patrick | EVP, CFO and Treasurer | M | 43,167 | $0.00 | $0.00 |
| Mar 3, 2026 | O'Hara Elaine | EVP, Chief Strategy Officer | M | 56,334 | $0.00 | $0.00 |
| Mar 3, 2026 | O'Hara Elaine | EVP, Chief Strategy Officer | M | 56,334 | $0.00 | $0.00 |
| Mar 3, 2026 | Casey Mark J | EVP, Chief Legal Officer | M | 4,000 | $0.00 | $0.00 |
| Mar 3, 2026 | Draghia-Akli Ruxandra | EVP, Research & Development | D | 26,667 | $0.00 | $0.00 |
| Mar 3, 2026 | Kelly James Patrick | EVP, CFO and Treasurer | M | 43,167 | $0.00 | $0.00 |
| Mar 3, 2026 | Jacobs John C | President and CEO | M | 150,167 | $0.00 | $0.00 |
| Mar 3, 2026 | Jacobs John C | President and CEO | M | 150,167 | $0.00 | $0.00 |
| Mar 3, 2026 | Casey Mark J | EVP, Chief Legal Officer | M | 37,500 | $0.00 | $0.00 |
| Mar 3, 2026 | Draghia-Akli Ruxandra | EVP, Research & Development | M | 26,667 | $0.00 | $0.00 |
| Mar 2, 2026 | Draghia-Akli Ruxandra | EVP, Research & Development | A | 139,500 | $0.00 | $0.00 |
| Mar 2, 2026 | Draghia-Akli Ruxandra | EVP, Research & Development | A | 93,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Draghia-Akli Ruxandra | EVP, Research & Development | A | 139,500 | $9.09 | $1.3M |
| Mar 2, 2026 | Jacobs John C | President and CEO | A | 367,500 | $0.00 | $0.00 |
| Mar 2, 2026 | Jacobs John C | President and CEO | A | 551,500 | $9.09 | $5.0M |
| Mar 2, 2026 | Kelly James Patrick | EVP, CFO and Treasurer | A | 194,000 | $9.09 | $1.8M |
| Mar 2, 2026 | O'Hara Elaine | EVP, Chief Strategy Officer | A | 118,000 | $0.00 | $0.00 |
| Mar 2, 2026 | O'Hara Elaine | EVP, Chief Strategy Officer | A | 177,500 | $9.09 | $1.6M |
| Mar 2, 2026 | Casey Mark J | EVP, Chief Legal Officer | A | 101,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Casey Mark J | EVP, Chief Legal Officer | A | 152,000 | $9.09 | $1.4M |
| Mar 2, 2026 | Kelly James Patrick | EVP, CFO and Treasurer | A | 129,500 | $0.00 | $0.00 |
| Mar 2, 2026 | O'Hara Elaine | EVP, Chief Strategy Officer | A | 177,500 | $0.00 | $0.00 |
| Mar 2, 2026 | Jacobs John C | President and CEO | A | 551,500 | $0.00 | $0.00 |
| Mar 2, 2026 | Casey Mark J | EVP, Chief Legal Officer | A | 152,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Kelly James Patrick | EVP, CFO and Treasurer | A | 194,000 | $0.00 | $0.00 |
| Mar 1, 2026 | Jacobs John C | President and CEO | M | 83,333 | $0.00 | $0.00 |
| Mar 1, 2026 | O'Hara Elaine | EVP, Chief Strategy Officer | M | 19,600 | $0.00 | $0.00 |
| Mar 1, 2026 | Casey Mark J | EVP, Chief Legal Officer | M | 4,000 | $0.00 | $0.00 |
| Mar 1, 2026 | Casey Mark J | EVP, Chief Legal Officer | M | 4,000 | $0.00 | $0.00 |
| Mar 1, 2026 | Jacobs John C | President and CEO | M | 83,333 | $0.00 | $0.00 |
| Mar 1, 2026 | Kelly James Patrick | EVP, CFO and Treasurer | M | 58,666 | $0.00 | $0.00 |
| Mar 1, 2026 | Kelly James Patrick | EVP, CFO and Treasurer | D | 58,666 | $0.00 | $0.00 |
| Mar 1, 2026 | O'Hara Elaine | EVP, Chief Strategy Officer | M | 19,600 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.7/10.
NEUTRAL
8-K
4/10
Novavax reported Q1 2026 total revenue of $140M, down 79% YoY from $667M, which included $603M in no
May 6, 2026
NEUTRAL
DEFA14A
2/10
Novavax has filed definitive additional proxy materials, indicating an active shareholder vote or co
Apr 27, 2026
BULLISH
8-K
8/10
Novavax reported strong financial results for Q4 and full year 2025, with revenue up 67% YoY to $147
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (67% buy). Based on 15 analysts: 4 strong buy, 6 buy, 2 hold, 2 sell, 1 strong sell.
Analyst Price Targets
$14.11 mean target
+65.0% upside
Strong Buy (2.33)
$7.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $8.56 |
| Target Low | $7.00 |
| Target Mean | $14.11 |
| Target Median | $16.02 |
| Target High | $25.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (2.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.40 | $-0.50 | $-0.26 | -164.5% | -200.9% | 0↑ 4↓ | $0.1B | -75.7% | 6 |
| Next Q 2026-09-30 |
$-0.15 | $-0.44 | $0.22 | 87.7% | -618.6% | 0↑ 3↓ | $0.1B | 53.4% | 5 |
| Current FY 2026-12-31 |
$-0.47 | $-1.38 | $0.52 | -118.3% | -27.2% | 1↑ 6↓ | $0.4B | -63.5% | 9 |
| Next FY 2027-12-31 |
$-0.25 | $-0.85 | $0.80 | 46.2% | +22.9% | 4↑ 1↓ | $0.3B | -37.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.400 | |
| 7d ago | $-0.152 | -0.248 |
| 30d ago | $-0.133 | -0.267 |
| 60d ago | $-0.137 | -0.263 |
| 90d ago | $0.188 | -0.587 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | TD Cowen | MAINTAIN | Hold | Hold |
| Feb 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 2 | 2 | 1 | 67% | |
| May 1, 2026 | 4 | 6 | 2 | 2 | 1 | 67% | |
| Apr 1, 2026 | 4 | 6 | 2 | 2 | 1 | 67% | |
| Mar 1, 2026 | 4 | 6 | 2 | 2 | 1 | 67% | |
| Feb 1, 2026 | 4 | 6 | 2 | 2 | 1 | 67% | |
| Jan 1, 2026 | 4 | 6 | 2 | 2 | 1 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
63°
Warm
Bearish
Neutral
Bullish
4 mentions
2 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 8, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 8, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
NVAX calls LFG
▲ 1
💬 1
⚡ 0.5
$NVAX calls ftw!
▲ 2
💬 1
⚡ 0.5
Jun 5, 2026
Clinical Trial
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
Phase Phase 3 — COMPLETED
May 28, 2026
short_volume
Short Volume: NVAX — 56.8% short (1.9M / 3.4M)
Short: 1,925,087 | Exempt: 5,156 | TRF Vol: 3,386,560 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 23, 2026
Clinical Trial
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
Phase Phase 3 — COMPLETED
May 22, 2026
short_volume
Short Volume: NVAX — 57.2% short (1.3M / 2.3M)
Short: 1,307,115 | Exempt: 809 | TRF Vol: 2,285,247 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 11, 2026
short_interest
FTD: NVAX — 60,633 shares ($0.6M) failed to deliver
Settlement: 20260511, Price: $10.11, FTD Value: $612,999.63, NOVAVAX INC COM NEW (DE)
May 8, 2026
short_interest
FTD: NVAX — 736,665 shares ($6.8M) failed to deliver
Settlement: 20260508, Price: $9.23, FTD Value: $6,799,417.95, NOVAVAX INC COM NEW (DE)
May 7, 2026
short_interest
FTD: NVAX — 119,707 shares ($1.1M) failed to deliver
Settlement: 20260507, Price: $9.36, FTD Value: $1,120,457.52, NOVAVAX INC COM NEW (DE)
May 6, 2026
earnings_calendar
NVAX Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
short_volume
Short Volume: NVAX — 63.4% short (0.9M / 1.4M)
Short: 891,231 | Exempt: 661 | TRF Vol: 1,406,623 | Short Ratio: 63.4% | Off-exchange volume (dark pool + OTC)
May 4, 2026
short_volume
Short Volume: NVAX — 56.9% short (0.7M / 1.3M)
Short: 744,064 | Exempt: 18 | TRF Vol: 1,307,456 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_interest
FTD: NVAX — 139,587 shares ($1.1M) failed to deliver
Settlement: 20260501, Price: $7.93, FTD Value: $1,106,924.91, NOVAVAX INC COM NEW (DE)
Apr 27, 2026
clinical_trial_readout
T-90d Trial Readout: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant (Phase 3)
Trial: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
Sponsor: Novavax
Phase: Phase 3 | Statu
Apr 22, 2026
short_volume
Short Volume: NVAX — 70.6% short (1.3M / 1.9M)
Short: 1,333,843 | Exempt: 573 | TRF Vol: 1,889,474 | Short Ratio: 70.6% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
Clinical Trial
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
Phase Phase 3 — COMPLETED
Apr 14, 2026
short_interest
FTD: NVAX — 74,688 shares ($0.6M) failed to deliver
Settlement: 20260414, Price: $8.11, FTD Value: $605,719.68, NOVAVAX INC COM NEW (DE)
Apr 10, 2026
short_volume
Short Volume: NVAX — 59.0% short (0.9M / 1.5M)
Short: 858,187 | Exempt: 7,065 | TRF Vol: 1,455,264 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
short_volume
Short Volume: NVAX — 60.4% short (0.8M / 1.3M)
Short: 809,027 | Exempt: 0 | TRF Vol: 1,339,990 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Feb 26, 2026
earnings_calendar
NVAX Q4 2025 Earnings After Market Close — 2026-02-26